MarginsXMarginsX
Home › Markets › Health Care › IRON

Disc Medicine Inc. (IRON)

IRON trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$76.59
-4.26% on the day
Market cap
$3.5B
Mid cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerIRON on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001816736
SEC industry codePharmaceutical Preparations

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
5.7 months
$90.0M cash at September 30, 2026
Share count, 1 year
+20.6%
2025-10-31 to 2026-10-29 · +88.6% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$119.1M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$90.0M cash; operating cash flow -$47.5M a quarter.Report 2026-09-30
Shares outstanding45,540,842 (2026-10-29); 37,750,162 a year earlier; 24,140,428 three years earlier.Cover page 2026-10-29
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-11-05
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-10
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $119.1M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$59.5M-$40.2M$90.0M$59.7MNeeds four quarters10-Q 2026-11-05
Q2 2026
2026-06-30
Not filed-$59.5M-$44.2M$98.7M$59.3MNeeds four quarters10-Q 2026-11-05
Q1 2026
2026-03-31
Not filed-$63.5M-$62.2M$88.9M$29.4MNeeds four quarters10-Q 2026-11-05
Q4 2025
2025-12-31
Not filed-$60.5M-$43.3M$91.1M$29.2MNeeds four quarters10-K 2026-02-26
Q3 2025
2025-09-30
Not filed-$62.3M-$47.8M$140.7M$28.9MNeeds four quarters10-Q 2026-11-05
Q2 2025
2025-06-30
Not filed-$55.2M-$47.9M$127.3M$28.7MNeeds four quarters10-Q 2026-11-05
Q1 2025
2025-03-31
Not filed-$34.1M-$41.4M$122.7M$28.5MNeeds four quarters10-Q 2026-11-05
Q4 2024
2024-12-31
Not filed-$29.5M-$27.6M$192.4M$28.3MNeeds four quarters10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-11-05
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 780 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+1.4%
1 month+41.3%
3 months-0.0%
Year to date+0.7%
1 year-8.1%
From 52-week high-15.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ELVNEnliven Therapeutics Inc.$47.62-2.42%$3.5B
PBLSParabilis Medicines Inc.$28.45+0.07%$3.5B
ARQTArcutis Biotherapeutics Inc.$27.15-3.93%$3.4B
VKTXViking Therapeutics Inc.$26.80-8.28%$3.4B
AMLXAmylyx Pharmaceuticals Inc.$27.80-8.22%$3.6B
VRDNViridian Therapeutics Inc.$29.80-3.47%$3.4B
ABCLAbCellera Biologics Inc. Common Shares$11.12-3.22%$3.6B
OGNOrganon & Co. Common Stock$13.900.00%$3.7B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier